How much does hyperhidrosis treatment cost?

There is no single reliable figure; it depends on location, severity, treatment choice, and insurance. As one worked example, a Japanese study estimated annual direct medical costs of roughly ¥75,000-93,000 per axillary hyperhidrosis patient (about US$680-850 at 2016-2018 rates), with botulinum toxin injections making up about 90% of that. Individual costs vary widely.

What drives the direct medical cost?

In the Japanese cost-of-illness study, botulinum toxin type A injections accounted for approximately 90% of direct medical costs each year. Prescription antiperspirants, office visits, oral medicines, and procedures make up the rest. Everyday over-the-counter products and clothing are additional out-of-pocket costs not captured in those figures.

Do most people with excessive sweating get treated?

Often not. A US survey found only 51% of people with excessive sweating had ever discussed it with a healthcare professional, and among diagnosed US patients, 12-month treatment rates were modest: about 51.6% for prescription antiperspirants, 13.1% for oral systemic therapy, and 1% or fewer for surgery (Doolittle 2016; Klein 2020).

Why don't more people seek care?

In the US survey, the main barriers were a belief that excessive sweating is not a medical condition and that no treatment options exist, awareness gaps as much as cost. Cost, insurance coverage, and access still shape whether treatment happens once care is sought.

Are the indirect (productivity) costs really significant?

They appear substantial. In the Japanese study, working patients reported about 30.5% overall work impairment, and non-working respondents reported about 49% activity impairment, which the authors valued at roughly ¥120,000-176,000 in monthly productivity loss per person. These rest on self-reported impairment and wage assumptions, so they are estimates.

Will my insurance cover treatment?

It varies by plan and country. Some treatments are approved but may require prior authorization, and certain procedures are frequently paid out of pocket. Because coverage and out-of-pocket costs differ so much, checking directly with your insurer and clinician is the only way to know your own likely cost.

Research

The Cost of Hyperhidrosis Treatment: What We Know

There is no single reliable dollar figure for "the cost of hyperhidrosis," because it depends on where a person lives, how severe their sweating is, which treatments they use, and whether costs are counted as direct medical spending, out-of-pocket products, or lost productivity. What the research does show is consistent in direction: excessive sweating carries real direct and indirect costs, insurance and awareness gaps limit access, and only about half of affected people ever discuss it with a healthcare professional. This page gathers the verified figures that exist and labels what each one measures. Individual costs vary widely; this is general information, not financial or medical advice.

By the Sweat Explained Editorial Team · Published 2026-07-13 · Last reviewed 2026-07-13 · Educational information, not medical advice.

Key statistics at a glance

51%
of people with excessive sweating have ever discussed it with a healthcare professional (US survey)
Doolittle 2016
≤1%
of diagnosed US patients received surgical treatment; 13.1% received oral systemic therapy
Klein 2020 (Optum claims)
≈¥75,000–93,000/yr
annual direct medical cost per axillary hyperhidrosis patient, Japan (roughly US$680–850)
Murota 2021
~90%
share of those direct medical costs attributable to botulinum toxin injections (Japan)
Murota 2021
30.5%
average overall work impairment among working patients with axillary hyperhidrosis (Japan)
Murota 2021

Why the cost is hard to pin down

Cost estimates for hyperhidrosis fall into three buckets that are rarely measured together. Direct medical costs are what is spent on clinical care: office visits, prescription antiperspirants, botulinum toxin injections, oral medicines, and procedures. Out-of-pocket costs include everyday spending on over-the-counter antiperspirants, absorbent products, and replacement clothing, much of which never appears in medical records. Indirect costs are the value of lost productivity: reduced output at work (presenteeism) and missed days (absenteeism).

Because studies measure different buckets, in different countries, using different methods, there is no universal figure to quote. The most defensible approach is to report each figure with its assumptions and to avoid collapsing them into one number. The figures below are labeled by what they measure and where they come from.

Direct medical costs: a worked example from Japan

The clearest published direct-cost estimate comes from a cost-of-illness study using a Japanese health-insurance claims database (1,447 patients) plus a web survey (321 patients). It is specific to Japan and to axillary (underarm) hyperhidrosis, so the yen amounts should not be read as universal, but the breakdown is informative. The approximate US-dollar figures below use 2016-2018 exchange rates (about ¥110 per US$) and are rough conversions only.

Annual direct medical cost per axillary hyperhidrosis patient, Japan (Murota 2021)
Year	Direct medical cost per patient	Approx. US$
2016	¥91,491	~$830
2017	¥93,155	~$845
2018	¥75,036	~$680

Botulinum toxin type A injections accounted for approximately 90% of these direct medical costs in each year. USD figures are approximate conversions at 2016-2018 rates, for scale only.

Access and utilization gaps

Cost is only part of the access picture. Large datasets show that many people with hyperhidrosis are never diagnosed and never treated, and that treatment, when it happens, is often low-intensity.

About half never raise it with a clinician. In a US survey of 8,160 people (Doolittle 2016), an estimated 4.8% had hyperhidrosis (~15.3 million people), 70% reported severe sweating in at least one body area, yet only 51% had ever discussed it with a healthcare professional.
Common reasons were beliefs, not just cost. The same survey found the main barriers were a belief that excessive sweating is not a medical condition and that no treatment options exist.
Treatment is often minimal. In a US claims analysis of 44,484 diagnosed patients (Klein 2020), within 12 months of diagnosis only 51.6% received a prescription-strength antiperspirant, 13.1% received oral systemic therapy, and 1% or fewer received surgical treatment. Adherence to prescription antiperspirants was low (about 13% of days covered).
Coverage varies by plan and country. Some treatments (for example botulinum toxin for the underarm) are approved but may require prior authorization, and energy-based procedures are frequently paid out of pocket, so a person's actual spending depends heavily on their insurance.

Indirect costs: lost productivity

Indirect costs may rival or exceed direct medical costs, though they are measured less often. In the Japanese study, patients reported substantial impairment in work and daily activities, which the authors translated into monthly productivity losses.

Self-reported impairment among people with axillary hyperhidrosis, Japan (Murota 2021)

Self-reported impairment among people with axillary hyperhidrosis, Japan (Murota 2021)
Group	Value
Overall work impairment (working patients)	30.52% (≈ ¥120,593 monthly productivity loss per working patient)
Activity impairment (non-working respondents)	49.05% (≈ ¥176,368 monthly loss)

Source: Murota H, et al. Cost-of-illness study, J Dermatol 2021. Chart is an original rendering of the cited data.

How to read these numbers

Three cautions apply. First, the dollar and yen figures come from one country (Japan) and one body area (the underarm); they illustrate scale and structure (for instance that a single treatment, botulinum toxin, can dominate direct spending) rather than a universal price tag. Second, the US figures here (Doolittle, Klein) describe access and utilization, not personal cost, so they show how many people are treated, not how much each pays. Third, indirect costs from lost productivity appear large but rest on self-reported impairment translated into wages, which involves assumptions.

The dependable, cross-study takeaways are qualitative: hyperhidrosis generates direct medical costs, ongoing out-of-pocket product costs, and meaningful lost productivity; a large share of affected people never seek care; and among those diagnosed, treatment is frequently limited. Anyone weighing the cost of care for their own situation should talk with a clinician and their insurer, since coverage and out-of-pocket costs vary widely.

Methodology and limitations

This page combines a US prevalence and help-seeking survey (Doolittle 2016, n=8,160), a US insurance-claims analysis of treatment patterns (Klein 2020, 44,484 diagnosed patients from the Optum Research Database), and a Japanese cost-of-illness study (Murota 2021, 1,447 claims patients plus a 321-person survey). Qualitative context on unmet care needs draws on Kamudoni 2017. Each figure was traced to its source and confirmed.

Limitations and assumptions: direct-cost figures are Japan-specific, cover axillary hyperhidrosis only, and are shown in yen with approximate US-dollar conversions at 2016-2018 exchange rates for scale. US figures describe utilization and access, not individual out-of-pocket cost. Indirect (productivity) costs rely on self-reported impairment converted to monetary value, which depends on wage assumptions. No single universal cost figure is presented because none is supported by the evidence. Individual costs vary widely, and nothing here is financial or medical advice.

Frequently asked questions

How much does hyperhidrosis treatment cost?: There is no single reliable figure; it depends on location, severity, treatment choice, and insurance. As one worked example, a Japanese study estimated annual direct medical costs of roughly ¥75,000-93,000 per axillary hyperhidrosis patient (about US$680-850 at 2016-2018 rates), with botulinum toxin injections making up about 90% of that. Individual costs vary widely.
What drives the direct medical cost?: In the Japanese cost-of-illness study, botulinum toxin type A injections accounted for approximately 90% of direct medical costs each year. Prescription antiperspirants, office visits, oral medicines, and procedures make up the rest. Everyday over-the-counter products and clothing are additional out-of-pocket costs not captured in those figures.
Do most people with excessive sweating get treated?: Often not. A US survey found only 51% of people with excessive sweating had ever discussed it with a healthcare professional, and among diagnosed US patients, 12-month treatment rates were modest: about 51.6% for prescription antiperspirants, 13.1% for oral systemic therapy, and 1% or fewer for surgery (Doolittle 2016; Klein 2020).
Why don't more people seek care?: In the US survey, the main barriers were a belief that excessive sweating is not a medical condition and that no treatment options exist, awareness gaps as much as cost. Cost, insurance coverage, and access still shape whether treatment happens once care is sought.
Are the indirect (productivity) costs really significant?: They appear substantial. In the Japanese study, working patients reported about 30.5% overall work impairment, and non-working respondents reported about 49% activity impairment, which the authors valued at roughly ¥120,000-176,000 in monthly productivity loss per person. These rest on self-reported impairment and wage assumptions, so they are estimates.
Will my insurance cover treatment?: It varies by plan and country. Some treatments are approved but may require prior authorization, and certain procedures are frequently paid out of pocket. Because coverage and out-of-pocket costs differ so much, checking directly with your insurer and clinician is the only way to know your own likely cost.

Sources

Primary peer-reviewed studies and official sources first, then reviews and institutional framing (secondary).

Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743-749. PMID 27744497. PubMed
Klein SZ, Hull M, Gillard KK, Peterson-Brandt J. Treatment patterns, depression, and anxiety among US patients diagnosed with hyperhidrosis: a retrospective cohort study. Dermatol Ther (Heidelb). 2020;10(6):1299-1314. Full text
Murota H, Fujimoto T, Oshima Y, et al. Cost-of-illness study for axillary hyperhidrosis in Japan. J Dermatol. 2021;48(10):1482-1490. Full text
Kamudoni P, Mueller B, Halford J, Schouveller A, Stacey B, Salek MS. The impact of hyperhidrosis on patients' daily life and quality of life: a qualitative investigation. Health Qual Life Outcomes. 2017;15:121. Qualitative; unmet health care needs. (secondary) Full text

How to cite this page

Sweat Explained. The Cost of Hyperhidrosis Treatment: What We Know. Published 2026-07-13; last reviewed 2026-07-13. Available at: https://sweatexplained.com/research/hyperhidrosis-treatment-costs-and-access

Please cite the original studies for the underlying figures. Journalists are welcome to link to this page; the charts are original renderings of the cited data.